1-6 of 6 results for subject:Fezolinetant
Librarians' tools
- Search time
- 0.204 seconds
- Solr query time
- 0.001 seconds
- Search query
- subject:Fezolinetant
- We searched for
- subject_t:Fezolinetant OR subject_t:Veoza OR subject_ses:585770
Type
House
Session
Year
Department
Member
Primary member
Answering member
Legislative stage
Legislation
Subject
Publisher
To ask the Secretary of State for Health and Social Care, whether he has had discussions with NHS England on access to fezolinetant within Leicester, Leicestershire and Rutland Integrated Care Board.
To ask the Secretary of State for Health and Social Care, whether he has had discussions with NHS England on access to fezolinetant within Leicester, Leicestershire and Rutland Integrated Care Board.
The National Institute for Health and Care Excellence (NICE) published guidance on 31 March 2026 recommending fezolinetant as an option for treating moderate to severe menopause-related hot flushes and night sweats when hormone replacement therapy is unsuitable. The National Health Service in England is legally required to fund medicines recommended by NICE, usually within three months of final guidance. This means integrated care boards (ICBs) are now required to fund fezolinetant in line with NICE’s recommendation. It remains for clinicians to decide whether it is the right treatment for an individual patient.
The Department has not assessed whether access to fezolinetant varies between the regions of England. It has also not had discussions with NHS England about access to fezolinetant in the Leicester, Leicestershire and Rutland ICB.
NHS England has not issued separate national guidance to ICBs on prescribing fezolinetant.
To ask the Secretary of State for Health and Social Care, what assessment he has made of levels of regional variation in access to fezolinetant across England.
To ask the Secretary of State for Health and Social Care, what assessment he has made of levels of regional variation in access to fezolinetant across England.
The National Institute for Health and Care Excellence (NICE) published guidance on 31 March 2026 recommending fezolinetant as an option for treating moderate to severe menopause-related hot flushes and night sweats when hormone replacement therapy is unsuitable. The National Health Service in England is legally required to fund medicines recommended by NICE, usually within three months of final guidance. This means integrated care boards (ICBs) are now required to fund fezolinetant in line with NICE’s recommendation. It remains for clinicians to decide whether it is the right treatment for an individual patient.
The Department has not assessed whether access to fezolinetant varies between the regions of England. It has also not had discussions with NHS England about access to fezolinetant in the Leicester, Leicestershire and Rutland ICB.
NHS England has not issued separate national guidance to ICBs on prescribing fezolinetant.
To ask the Secretary of State for Health and Social Care, whether national guidance has been issued to Integrated Care Boards on the prescribing of fezolinetant following its approval for NHS use.
To ask the Secretary of State for Health and Social Care, whether national guidance has been issued to Integrated Care Boards on the prescribing of fezolinetant following its approval for NHS use.
The National Institute for Health and Care Excellence (NICE) published guidance on 31 March 2026 recommending fezolinetant as an option for treating moderate to severe menopause-related hot flushes and night sweats when hormone replacement therapy is unsuitable. The National Health Service in England is legally required to fund medicines recommended by NICE, usually within three months of final guidance. This means integrated care boards (ICBs) are now required to fund fezolinetant in line with NICE’s recommendation. It remains for clinicians to decide whether it is the right treatment for an individual patient.
The Department has not assessed whether access to fezolinetant varies between the regions of England. It has also not had discussions with NHS England about access to fezolinetant in the Leicester, Leicestershire and Rutland ICB.
NHS England has not issued separate national guidance to ICBs on prescribing fezolinetant.
To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure consistent access across Integrated Care Boards to non-hormonal menopause treatments, including fezolinetant.
To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure consistent access across Integrated Care Boards to non-hormonal menopause treatments, including fezolinetant.
The National Institute for Health and Care Excellence (NICE) published guidance on 31 March 2026 recommending fezolinetant as an option for treating moderate to severe menopause-related hot flushes and night sweats when hormone replacement therapy is unsuitable. The National Health Service in England is legally required to fund medicines recommended by NICE, usually within three months of final guidance. This means integrated care boards (ICBs) are now required to fund fezolinetant in line with NICE’s recommendation. It remains for clinicians to decide whether it is the right treatment for an individual patient.
The Department has not assessed whether access to fezolinetant varies between the regions of England. It has also not had discussions with NHS England about access to fezolinetant in the Leicester, Leicestershire and Rutland ICB.
NHS England has not issued separate national guidance to ICBs on prescribing fezolinetant.
To ask the Secretary of State for Health and Social Care, what discussions he has had with healthcare professionals on the suitability of prescribing fezolinetant for routine use.
To ask the Secretary of State for Health and Social Care, what discussions he has had with healthcare professionals on the suitability of prescribing fezolinetant for routine use.
Fezolinetant is a non-hormonal medicine used to treat moderate to severe hot flushes and night sweats linked to menopause. It may be used where hormone replacement therapy is not suitable.
The National Institute for Health and Care Excellence (NICE) published guidance on 31 March 2026 recommending fezolinetant as an option for treating these symptoms when hormone replacement therapy is unsuitable. NICE is the independent body that assesses whether medicines should be routinely funded by the National Health Service, based on clinical and cost effectiveness. Once NICE recommends a medicine, the NHS in England is normally legally required to fund it within three months of the final guidance. Integrated care boards are therefore expected to make fezolinetant available in line with NICE’s recommendation. Decisions about whether it is right for an individual patient remain for clinicians to make with their patients.
To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of the potential merits of introducing fezolinetant for routine use.
To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of the potential merits of introducing fezolinetant for routine use.
Fezolinetant is a non-hormonal medicine used to treat moderate to severe hot flushes and night sweats linked to menopause. It may be used where hormone replacement therapy is not suitable.
The National Institute for Health and Care Excellence (NICE) published guidance on 31 March 2026 recommending fezolinetant as an option for treating these symptoms when hormone replacement therapy is unsuitable. NICE is the independent body that assesses whether medicines should be routinely funded by the National Health Service, based on clinical and cost effectiveness. Once NICE recommends a medicine, the NHS in England is normally legally required to fund it within three months of the final guidance. Integrated care boards are therefore expected to make fezolinetant available in line with NICE’s recommendation. Decisions about whether it is right for an individual patient remain for clinicians to make with their patients.